Drug intelligence / Profile preview

CRA-9334

Development stage: Unknown
Modality: Small Molecules

Overview

CRA‑9334 is an experimental small molecule belonging to the class of phenylbenzimidazoles, characterized by a benzimidazole moiety attached to a phenyl group. Its chemical formula is C15H13BrN4O and it has a molecular weight of approximately 345.19 g/mol[1][2]. The compound is primarily referenced in research contexts and does not have an established clinical indication or detailed mechanism of action publicly available. It has been studied for its pharmacokinetic properties, including high predicted human intestinal absorption and blood-brain barrier permeability[1]. No approved therapeutic use or specific disease target has been reported.

Other names: 2-{5-[amino(iminio)methyl]-1H-benzimidazol-2-yl}-6-bromo-4-methylphenolate2-(3-Bromo-2-hydroxy-5-methylphenyl)-1H-benzoimidazole–5-carboxamidine

Beyond the preview

Go deeper on CRA-9334.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CRA-9334.

Explore the full profile